Medtronic announces results showing meaningful pain relief using dtm™ spinal cord stimulation endurance therapy

Dtm™ scs endurance therapy enables long-lasting recharge-free performance on vanta™ and 5-minute recharge on intellis™ neurostimulators dublin, jan. 14, 2022 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study1 showing meaningful pain relief using dtm™ scs endurance therapy, a modified, lower-energy variation of the company's differential target multiplexed™ (dtm) spinal cord stimulation (scs) therapy for chronic overall, back or leg pain. at 3 months, patients treated with dtm scs endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm visual analog scale (vas)2.
MDT Ratings Summary
MDT Quant Ranking